Kst Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 10.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 9.40 Cr
as on 16-12-2024
- Company Age 5 Year, 12 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 48.84 Cr
as on 16-12-2024
- Revenue %
(FY 2022)
- Net Worth 554.63%
(FY 2022)
- Total Assets 1727.48%
(FY 2022)
About Kst Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 10.00 Cr and a paid-up capital of Rs 9.40 Cr.
The company currently has active open charges totaling ₹48.84 Cr.
Kalyan Vankayalapati and Surapaneni Tarunya serve as directors at the Company.
- CIN/LLPIN
U24290TG2019PTC137497
- Company No.
137497
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Kst Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kalyan Vankayalapati  | Director | 11-Dec-2019 | Current |
| Surapaneni Tarunya | Director | 11-Dec-2019 | Current |
Financial Performance of Kst Pharmaceuticals.
Kst Pharmaceuticals Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 554.63%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Kst Pharmaceuticals?
In 2022, Kst Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Satya Kalyan Constructions Private LimitedActive 29 years 7 months
Kalyan Vankayalapati is a mutual person
- Satya Kalyan Pharmaceuticals Private LimitedActive 10 years 4 months
Kalyan Vankayalapati is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 25 May 2023 | ₹23.84 Cr | Open |
Canara Bank Creation Date: 15 Jun 2021 | ₹25.00 Cr | Open |
How Many Employees Work at Kst Pharmaceuticals?
Kst Pharmaceuticals has a workforce of 52 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Kst Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Kst Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
